Novavax focuses on urgent health challenges, which is evaluating vaccines for COVID-19 and influenza, as well as COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on product candidates for respiratory syncytial virus and malaria.
The company has 36% of the float sold short. H.C. Wainwright has a $35 target price, while the consensus target is $22.00. The stock closed on Thursday at $7.59.
C3ai
This stock exploded higher after the initial public offering in 2021 and proceeded to give it all back, but interest in artificial intelligence (AI) has turned the stock around. C3.AI Inc. (NYSE: AI) operates as an enterprise AI software company in North America, Europe, the Asia Pacific and elsewhere.
The company’s C3 AI platform is an application development and runtime environment that enables customers to design, develop and deploy enterprise AI applications. It offers C3 AI Ex Machina for analysis-ready data; C3 AI CRM, an industry-specific customer relationship management solution; and C3 Generative AI Product Suite that enables customers to locate, retrieve and present information.
The company also offers these C3 AI applications:
- C3 AI Inventory Optimization, a solution to optimize raw material, in-process and finished goods inventory levels
- C3 AI Supply Network Risk, which identifies emerging inbound and outbound risks across the network
- C3 AI Sustainability Suite, which helps to decrease greenhouse gas emission
- C3 AI Production Schedule Optimization, a solution for scheduling production
- C3 AI Financial Services Suite, which helps to minimize compliance risks
- C3 AI Energy Management solution
In addition, it offers integrated turnkey enterprise AI applications for oil and gas, chemicals, utilities, manufacturing, financial services, defense, intelligence, aerospace, health care and telecommunications.
It has strategic partnerships with Baker Hughes in the areas of oil and gas market; Booz Allen to provide solutions to government, defense and intelligence sectors; Raytheon; and AWS, Google and Microsoft
Over 35% of its float is sold short. The Wedbush target price is $50. The $26.89 consensus target is less than Thursday’s $35.90 closing share price.
Lovesac
This company with the very confusing name is well liked across Wall Street and has a big short position that could launch it higher. Lovesac Co. (NASDAQ: LOVE) designs, manufactures and sells furniture.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
